Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07634471CT.gov A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | — | Not Yet Recruiting | — | — | — |
NCT06859008CT.gov Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT06911502CT.gov A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | — | Recruiting | — | — | — |
NCT06961500CT.gov Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A | — | Not Yet Recruiting | — | — | — |
NCT06563596CT.gov Epco, Zanu, Ritux for R/R FL or MZL | — | Recruiting | — | — | — |
NCT06704555CT.gov Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma | — | Recruiting | — | — | — |
NCT06425302CT.gov A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | — | Active Not Recruiting | — | — | — |
NCT06549595CT.gov A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | — | Recruiting | — | — | — |
NCT06471738CT.gov Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | — | Recruiting | — | — | — |
NCT06474481CT.gov Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma | — | Not Yet Recruiting | — | — | — |
Show 62 more trialsShow fewer
NCT06284122CT.gov Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 | — | Recruiting | — | — | — |
NCT06313996CT.gov A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | — | Withdrawn | — | — | — |
NCT06191744CT.gov Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | — | Recruiting | — | — | — |
NCT06091254CT.gov A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | — | Recruiting | — | — | — |
NCT06151080CT.gov Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | — | Recruiting | — | — | — |
NCT06097364CT.gov A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05888493CT.gov A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05890352CT.gov Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | — | Recruiting | — | — | — |
NCT05848765CT.gov Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | — | Recruiting | — | — | — |
NCT05899621CT.gov A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL | — | Recruiting | — | — | — |
NCT05583149CT.gov Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05455697CT.gov Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05934097CT.gov FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT05371093CT.gov Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04836832CT.gov Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | — | Withdrawn | — | — | — |
NCT05389293CT.gov A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma | — | Recruiting | — | — | — |
NCT05326308CT.gov Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma | — | Recruiting | — | — | — |
NCT05100862CT.gov A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | — | Recruiting | — | — | — |
NCT04883437CT.gov Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | — | Recruiting | — | — | — |
NCT05040555CT.gov R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden | — | Recruiting | — | — | — |
NCT04745832CT.gov Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | — | Terminated | — | — | — |
NCT04799275CT.gov Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04842318CT.gov Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study | — | Unknown | — | — | — |
NCT04257578CT.gov Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04663347CT.gov Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | — | Active Not Recruiting | — | — | — |
NCT04542824CT.gov Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | — | Active Not Recruiting | — | — | — |
NCT04404088CT.gov Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04323956CT.gov Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04282018CT.gov Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | — | Completed | — | — | — |
NCT04058470CT.gov Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | — | Unknown | — | — | — |
NCT03817853CT.gov An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | — | Completed | — | — | — |
NCT03269669CT.gov Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03332017CT.gov A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma | — | Completed | — | — | — |
NCT02700022CT.gov A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas | — | Terminated | — | — | — |
NCT02914938CT.gov A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT02889523CT.gov Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | — | Active Not Recruiting | — | — | — |
NCT02855359CT.gov Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | — | Terminated | — | — | — |
NCT02541565CT.gov Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma | — | Completed | — | — | — |
NCT02348216CT.gov Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02362035CT.gov ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | — | Completed | — | — | — |
NCT02208037CT.gov Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | — | Completed | — | — | — |
NCT01950273CT.gov Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | — | Completed | — | — | — |
NCT01897012CT.gov Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | — | Completed | — | — | — |
NCT01812005CT.gov Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT01852435CT.gov R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | — | Unknown | — | — | — |
NCT01567709CT.gov Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
NCT01397591CT.gov Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT01381692CT.gov Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | — | Completed | — | — | — |
NCT01286272CT.gov Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01193842CT.gov Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | — | Completed | — | — | — |
NCT00992446CT.gov Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00807495CT.gov Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00715208CT.gov Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma | — | Completed | — | — | — |
NCT00697346CT.gov Study of MLN8237 in Participants With Advanced Hematological Malignancies | — | Completed | — | — | — |
NCT00538187CT.gov Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT00907348CT.gov Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma | — | Unknown | — | — | — |
NCT00510887CT.gov Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma | — | Terminated | — | — | — |
NCT00348985CT.gov PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | — | Completed | — | — | — |
NCT00774826CT.gov Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma | — | Unknown | — | — | — |
NCT00103272CT.gov 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | — | Terminated | — | — | — |
NCT00096005CT.gov Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | — | Terminated | — | — | — |
NCT00082784CT.gov Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Follicular Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Merck Sharp & Dohme LLC | Approved | BB · 68 |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Romidepsin | City of Hope Medical Center | P2 | BBB |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2/3 | BBB |
| Recombinant Human Hyaluronidase | National Cancer Institute (NCI) | P3 | BBB |
| Irinotecan | University of Michigan Rogel Cancer Center | P2 | BBB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Bortezomib | Emory University | P2 | BB |
+42 more in the Follicular Lymphoma cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Follicular Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-follicular-lymphoma-21186
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →